標(biāo)題：Research Grade Urelumab烏瑞蘆單抗,AntibodySystem Laboratories

鏈接：https://www.antibodysystem.com/product/243.html

名稱：Research Grade Urelumab烏瑞蘆單抗

別名：Urelumab，烏瑞蘆單抗，抗體，BMS-663513

CAS: 934823-49-1

貨號(hào)：DHG11002

適用物種：Human

寄主物種：Homo sapiens

形式：Liquid

純度：>95%

克隆性：Monoclonal

同種型：IgG4-kappa

應(yīng)用：Research Grade Biosimilar

UniProt：Q07011

用途范圍：僅用于科研

靶點(diǎn)：Tumor necrosis factor receptor superfamily member 9, CD137, 4-1BB ligand receptor, CDw137, TNFRSF9, T-cell antigen ILA, T-cell antigen 4-1BB homolog, ILA

儲(chǔ)存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

產(chǎn)品購買聯(lián)系方式：027-65279366 /18162686757

郵箱：biolab-reagents@atagenix.com

QQ：2663991332

參考文獻(xiàn)：Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. PMID: 32052473

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. PMID: 36727218

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. PMID: 38458639

Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. PMID: 29118009

CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary. PMID: 36576322

FcgammaR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab. PMID: 37575254

Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity. PMID: 36248847

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells. PMID: 31143521

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. PMID: 35236742

Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. PMID: 30410017

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. PMID: 27756788

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rgammanull Immunodeficient Mice. PMID: 26113085

A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. PMID: 37339979

Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. PMID: 34168049

4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T. PMID: 37433196

CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development. PMID: 34064598

Checkpoint Inhibition in Non-Hodgkin's Lymphoma. PMID: 29065421

M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation. PMID: 38091375

Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents. PMID: 37310433

Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. PMID: 38309721

CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function. PMID: 34580116

CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. PMID: 27496866

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. PMID: 26137403

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. PMID: 23452415

A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity. PMID: 36076251

4-1BB costimulation promotes bystander activation of human CD8 T cells. PMID: 33180337

CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors. PMID: 38593226

Functional expression of CD137 (4-1BB) on T helper follicular cells. PMID: 26587331

Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic. PMID: 34172583

Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy. PMID: 38492435

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. PMID: 31105267

Costimulatory capacity of CD137 mAbs on T cells depends on elaborate CRD structures but not on blocking ligand-receptor binding. PMID: 37675596

CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes. PMID: 29133290

Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. PMID: 35110355

Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates. PMID: 36176235

In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in mice. PMID: 35820360

4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. PMID: 28473315

Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity. PMID: 31974274

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. PMID: 23460532